Speaking at a hearing in the European Union (EU) Parliament in Brussels on Monday, the European Medicines Agency (EMA) Head Guido Rasi said an initial authorization for US pharmaceutical company Gilead Sciences’ Remdesivir as a coronavirus treatment could be granted in coming days, per Reuters.
Rasi noted: “It might be that a conditional market authorization can be issued in the coming days.”
The shared currency is uninspired by the positive news, as EUR/USD turns negative and looks to break below the 1.08 handle. The spot trades at 1.0811, down 0.06% on the day.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.